MAPT and neurodegenerative disease: Concentrations of phosphorylated tau (p-tau) at threonine 181 (p-tau181), 217, or 231 are elevated in AD, including neuropathologically-confirmed cases and amyloid positive MCI-AD, relative to cognitively healthy individuals and many non-AD neurodegenerative diseases (Chong et al., 2021).